SAGA enters into research collaboration with University College London

LUND, Sweden — /June 17, 2020/ — SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announced a research collaboration with University College London (UCL) Cancer Institute.   In the course of this collaboration, SAGA will design…

SAGA Diagnostics enters supply agreement with the German Institute for Hematopathology Hamburg

LUND, Sweden – /June 4, 2020/ – SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and ultrasensitive monitoring of cancer patients, today announces it has entered a supply agreement with the German Institute for Hematopathology Hamburg, a large private pathology based in Hamburg,…

SAGA represented in oral presentations at AACR and ASCO annual meetings and in a peer reviewed article

LUND, Sweden – /May 28, 2020/ – SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announces recent breast cancer research results recognized at leading international cancer research and oncology conferences, AACR and ASCO, and a leukemia…

SAGA expands with two diagnostics scientists to further accelerate launch of new products and services

LUND, Sweden — /March 30, 2020/ — SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announces the appointment of two new team members to significantly strengthen SAGA’s R&D team: Sofia Birkeälv, PhD as Molecular Diagnostics Scientist, NGS Lead,…

SAGA Diagnostics extends its collaboration with Servier to use ultrasensitive SAGAsafe® technology in cancer clinical trials

LUND, Sweden – /January 28, 2020/ – SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announces it has entered service agreements with the international pharmaceutical company Servier, based in Paris, France. These deals exemplify the…

SAGA seeks sales executive Germany and sales executive Spain

2 POSITIONS: Sales Executive, Germany and Sales Executive, Spain SAGA Diagnostics AB is seeking a talented and highly motivated staff with strong interest in bringing a new technology to the market and thus advancing our mission to revolutionize cancer diagnostics through proprietary ultrasensitive technologies that measure circulating tumor DNA in…